Daniel Vigo1,2, Laura Jones3, Graham Thornicroft4, Rifat Atun5. 1. Department of Psychiatry, University of British Columbia, Vancouver, Canada. 2. Department of Global Health & Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA. 3. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 4. Institute of Psychiatry, Psychology & Neuroscience, King's College, London, United Kingdom. 5. Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Abstract
OBJECTIVE: To estimate the burden of mental, neurological, substance use disorders and self-harm (MNSS) in Canada, Mexico, and the United States. METHOD: We extracted 2017 data from the Global Burden of Disease online database. Based on a previously developed framework to classify and aggregate the burden of specific disorders and symptoms, we reestimated the MNSS burden to include suicide, alcohol use, drug use, specific neurological, and painful somatic symptom disorders. We analyzed age-sex-specific patterns within and between countries. RESULTS: The MNSS burden is the largest of all disorder groupings. It is lowest in Mexico, intermediate in Canada, and highest in the United States. Exceptions are alcohol use, bipolar, conduct disorders, and epilepsy, which are highest in Mexico; and painful somatic syndromes and headaches, which are highest in Canada. The burden of drug use disorders in the United States is twice the burden in Canada, and 7 times the burden in Mexico. MNSS become the most burdensome of all disorder groups by age 10, staying at the top until age 60, and show a distinct pattern across the lifetime. The top three MNSS disorders for men are a combination of substance use disorders and self-harm (United States), with the addition of painful somatic syndromes (Canada), and headaches (Mexico). For women, the top three are headaches and depression (all countries), drug use (United States), neurocognitive disorders (Mexico), and painful somatic syndromes (Canada). CONCLUSION: MNSS are the most burdensome disease grouping and should be prioritized for funding in Canada, Mexico, and the United States.
OBJECTIVE: To estimate the burden of mental, neurological, substance use disorders and self-harm (MNSS) in Canada, Mexico, and the United States. METHOD: We extracted 2017 data from the Global Burden of Disease online database. Based on a previously developed framework to classify and aggregate the burden of specific disorders and symptoms, we reestimated the MNSS burden to include suicide, alcohol use, drug use, specific neurological, and painful somatic symptom disorders. We analyzed age-sex-specific patterns within and between countries. RESULTS: The MNSS burden is the largest of all disorder groupings. It is lowest in Mexico, intermediate in Canada, and highest in the United States. Exceptions are alcohol use, bipolar, conduct disorders, and epilepsy, which are highest in Mexico; and painful somatic syndromes and headaches, which are highest in Canada. The burden of drug use disorders in the United States is twice the burden in Canada, and 7 times the burden in Mexico. MNSS become the most burdensome of all disorder groups by age 10, staying at the top until age 60, and show a distinct pattern across the lifetime. The top three MNSS disorders for men are a combination of substance use disorders and self-harm (United States), with the addition of painful somatic syndromes (Canada), and headaches (Mexico). For women, the top three are headaches and depression (all countries), drug use (United States), neurocognitive disorders (Mexico), and painful somatic syndromes (Canada). CONCLUSION: MNSS are the most burdensome disease grouping and should be prioritized for funding in Canada, Mexico, and the United States.
Entities:
Keywords:
Global Burden of Disease; North America; mental disorders; mental health; substance use disorders
Authors: Daniel V Vigo; Vikram Patel; Anne Becker; David Bloom; Winnie Yip; Giuseppe Raviola; Shekhar Saxena; Arthur Kleinman Journal: Lancet Psychiatry Date: 2019-01-29 Impact factor: 27.083
Authors: Joshua A Salomon; Juanita A Haagsma; Adrian Davis; Charline Maertens de Noordhout; Suzanne Polinder; Arie H Havelaar; Alessandro Cassini; Brecht Devleesschauwer; Mirjam Kretzschmar; Niko Speybroeck; Christopher J L Murray; Theo Vos Journal: Lancet Glob Health Date: 2015-11 Impact factor: 26.763
Authors: Nanna Weye; Maria K Christensen; Natalie C Momen; Kim Moesgaard Iburg; Oleguer Plana-Ripoll; John J McGrath Journal: Can J Psychiatry Date: 2019-12-09 Impact factor: 4.356
Authors: James Daniel Obray; Eun Young Jang; Anneke M Klomp; Christina A Small; Aaron P Richardson; Joshua J LeBaron; Jin Gyeom Lee; Jordan T Yorgason; Chae Ha Yang; Scott C Steffensen Journal: Alcohol Clin Exp Res Date: 2022-02-01 Impact factor: 3.455
Authors: Daniel Vigo; Wayne Jones; Naomi Dove; Daniel E Maidana; Corinne Tallon; Will Small; Hasina Samji Journal: Can J Psychiatry Date: 2021-04-08 Impact factor: 5.321
Authors: Giulio Castelpietra; Ann Kristin Skrindo Knudsen; Emilie E Agardh; Benedetta Armocida; Massimiliano Beghi; Kim Moesgaard Iburg; Giancarlo Logroscino; Rui Ma; Fabrizio Starace; Nicholas Steel; Giovanni Addolorato; Catalina Liliana Andrei; Tudorel Andrei; Jose L Ayuso-Mateos; Maciej Banach; Till Winfried Bärnighausen; Francesco Barone-Adesi; Akshaya Srikanth Bhagavathula; Felix Carvalho; Márcia Carvalho; Joht Singh Chandan; Vijay Kumar Chattu; Rosa A S Couto; Natália Cruz-Martins; Paul I Dargan; Keshab Deuba; Diana Dias da Silva; Adeniyi Francis Fagbamigbe; Eduarda Fernandes; Pietro Ferrara; Florian Fischer; Peter Andras Gaal; Alessandro Gialluisi; Juanita A Haagsma; Josep Maria Haro; M Tasdik Hasan; Syed Shahzad Hasan; Sorin Hostiuc; Licia Iacoviello; Ivo Iavicoli; Elham Jamshidi; Jost B Jonas; Tamas Joo; Jacek Jerzy Jozwiak; Srinivasa Vittal Katikireddi; Joonas H Kauppila; Moien A B Khan; Adnan Kisa; Sezer Kisa; Mika Kivimäki; Kamrun Nahar Koly; Ai Koyanagi; Manasi Kumar; Tea Lallukka; Berthold Langguth; Caterina Ledda; Paul H Lee; Ilaria Lega; Christine Linehan; Joana A Loureiro; Áurea M Madureira-Carvalho; Jose Martinez-Raga; Manu Raj Mathur; John J McGrath; Enkeleint A Mechili; Alexios-Fotios A Mentis; Tomislav Mestrovic; Bartosz Miazgowski; Andreea Mirica; Antonio Mirijello; Babak Moazen; Shafiu Mohammed; Francesk Mulita; Gabriele Nagel; Ionut Negoi; Ruxandra Irina Negoi; Vincent Ebuka Nwatah; Alicia Padron-Monedero; Songhomitra Panda-Jonas; Shahina Pardhan; Maja Pasovic; Jay Patel; Ionela-Roxana Petcu; Marina Pinheiro; Richard Charles G Pollok; Maarten J Postma; David Laith Rawaf; Salman Rawaf; Esperanza Romero-Rodríguez; Luca Ronfani; Dominic Sagoe; Francesco Sanmarchi; Michael P Schaub; Nigussie Tadesse Sharew; Rahman Shiri; Farhad Shokraneh; Inga Dora Sigfusdottir; João Pedro Silva; Renata Silva; Bogdan Socea; Miklós Szócska; Rafael Tabarés-Seisdedos; Marco Torrado; Marcos Roberto Tovani-Palone; Tommi Juhani Vasankari; Massimiliano Veroux; Russell M Viner; Andrea Werdecker; Andrea Sylvia Winkler; Simon I Hay; Alize J Ferrari; Mohsen Naghavi; Peter Allebeck; Lorenzo Monasta Journal: Lancet Reg Health Eur Date: 2022-04-01